We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Organon and Co | NYSE:OGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.83 | 0 | 09:00:03 |
From May 2021 to May 2024
By Stephen Nakrosis
Shares of biopharmaceutical company ObsEva SA rose on Tuesday, after the company said it entered a deal which will see Organon & Co. license the global development, manufacturing and commercial rights to ebopiprant.
At 3:20 p.m. ET, shares of ObsEva advanced 10.52% to $2.78. Volume topped 66.1 million shares, above the stock's 65-day average volume of 678,428.
At 3:17 p.m. ET, shares of Organon & Co. slid 2.07% to $29.03.
Ebopiprant is being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions, Organon said.
-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 27, 2021 15:46 ET (19:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Organon Chart |
1 Month Organon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
